
Background: Endovascular repair has become state of the art for treating thoracic and abdominal aortic aneurysms. However, complications such as endoleaks or the development of aortic neck dilatation, require lifelong surveillance and re-interventions. The extent to which structural vessel wall alterations during implantation of endovascular grafts are involved in the development of these complications is widely unknown. Therefore, the aim of this study was to characterize aortic vessel wall alterations during endovascular aortic repair in a porcine ex-vivo model. Methods: A total of 18 endovascular stent-grafts were implanted in a thoracoabdominal porcine aortic flow model. Subsequently, histomorphological analysis, transmission electron microscopy and biomechanical analysis of the proximal sealing zone was performed. Results: While histological wall impairment was detected in only four specimens (22%), transmission electron microscopy revealed ultrastructural disruption in all specimens after EVAR. Transmission electron microscopy revealed a disrupted structure of elastic fibers with microtears and cavities supplemented by ruptured collagen fibers and disrupted integrity of vascular smooth muscle cells in all aortic specimens after stent-graft implantation. As a biomechanical correlate to ultrastructural aortic wall injuries, a significantly lower force at rupture (55.63 +/- 14.71 vs. 36.56 +/- 12.27 N, P=0.006) and elongation at rupture (22.23 +/- 5.39 vs. 17.13 +/- 5.34 mm, P=0.048) were observed in aortic specimens after stent-graft implantation. Conclusions: Endovascular stent-graft implantation induces acute ultrastructural damage to the aortic wall, including elastic fiber disintegration, collagen disruption, and microdissections within the tunica media. These alterations were associated with reduced biomechanical stability. Whether this initial mechanical injury contributes to long-term complications such as aortic neck dilatation warrants further investigation.
Background: The aim of this study was to compare mid-term outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) when used as a bailout strategy for complex femoropopliteal lesions in real-world practice. Methods: Single-center, retrospective cohort (January 2018-February 2025) including patients requiring bailout stenting after suboptimal angioplasty. Primary endpoints included primary patency, freedom from clinically driven target lesion revascularization (cdTLR). Secondary endpoints were considered the limb loss, freedom from major adverse limb events (MALE) and all-cause mortality rate. Time-to-event outcomes were analyzed by Kaplan-Meier and log-rank testing up to 36 months; hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. A multivariable Cox model explored predictors of statistically significant outcomes. Results: A total of 141 patients were included (BMS 65; DES 76). Compared with DES, the BMS group had higher rates of diabetes (58.5% vs. 40.8, P=0.036), CKD (70.8% vs. 40.8, P<0.001), dialysis (12.3% vs. 1.3, P=0.008), CLTI (89.2% vs. 75.0, P=0.030), Rutherford 5-6 (69.2% vs. 52.6, P=0.045), and ASA >= 3 (100% vs. 89.5, P=0.007). Kaplan-Meier analyses showed no significant between-group differences for primary patency (log-rank chi(2) 0.0011, P=0.973; HR 0.99, 95% CI 0.43-2.27), freedom from cdTLR (chi(2) 1.6318, P=0.2015; HR 0.52, 0.19-1.41), limb loss (chi(2) 2.37, P=0.124; HR 4.03, 0.68-23.76), or freedom from MALE (chi(2) 0.68, P=0.409; HR 1.48, 0.58-3.79). The all-cause mortality rate in the unadjusted analysis resulted higher in the BMS group (log-rank chi(2) 13.09, P<0.0003); (HR 2.75; 95% CI 1.59-4.76). In multivariable analysis, mortality was independently associated with CKD (HR 3.43, P=0.001), dialysis (HR 2.70, P=0.012), tissue loss/Rutherford 5-6 (HR 2.54, P=0.006), and history for neoplasia (HR 1.96, P=0.028); stent type was not an independent predictor (BMS vs. DES HR 0.54, P=0.063). Conclusions: In bailout setting for long, complex femoropopliteal disease, stent type did not influence the outcomes post revascularization at 36 months. The overall all-cause mortality rate was driven by baseline clinical status rather than the device.
Background: Inflammatory abdominal aortic aneurysm (IAAA), a distinct clinical entity characterized by dense periaortic fibrosis and elevated inflammatory markers, lacks a consensus-driven optimal management strategy. While medical therapy is often utilized, comparative data against surgical or endovascular interventions remain limited. We report our experience with a standardized medical protocol for the management of IAAAs. Methods: We conducted aretrospective cohort study of 27 consecutive patients diagnosed with IAAA between 2012 and 2019. Predefined diagnostic criteria for IAAA included an ESR>100 mm/h, aortic wall thickness >10 mm, and inflammatory symptoms. Risk of rupture was assessed using a PET-CT scan for patients with a maximal aortic diameter exceeding 5.5 cm. A standardized medical protocol was used for low rupture risk patients including IV methylprednisolone followed by oral prednisone taper. Methotrexate was introduced for steroid-refractory cases. Endovascular or open aortic repair was used for patients with high risk of rupture. Results: Patients had a mean age of 62.3 years, and 70.4% were male. The mean baseline aortic diameter was 48 +/- 5 mm (95% CI 46.0-50.0). Twenty-three patients (85.2%) were treated initially with corticosteroids. At the 3-month mark, 69.6% of medically treated patients achieved an acceptable response with steroids alone. Five steroid-refractory patients received methotrexate and demonstrated clinical improvement. ESR normalized in 95.7% of medically treated patients. During five-year follow-up, no medically managed patient required emergency surgical intervention. Eleven patients required temporary steroid reintroduction at 3 years, with sustained stability at 5 years. Three patients underwent EVAR with favorable outcomes. One patient underwent open repair, which was associated with significant perioperative morbidity and late mortality. Conclusions: In selected patients with low risk of aortic rupture, protocol-based medical therapy for IAAA is safe and effective with minimal risk upon mid-term follow-up. PET-CT scan assessment for risk of immediate rupture is appropriate for patients with aortic diameter between 5.5 to 6.5 cm. Methotrexate introduction may be effective for steroid-refractory cases. Endovascular repair remains a suitable option when intervention is required. Larger prospective studies are needed to establish definitive management guidelines for IAAAs.